Immune responses during spontaneous control of HIV and AIDS: What is the hope for a cure?

Philosophical Transactions of the Royal Society B: Biological Sciences

Volumn 369, Issue 1645, 2014, Pages

  Saez Cirion, A ^a   Jacquelin, B ^a   Barre Sinoussi F ^a   Muller Trutwin M ^a  

^a INSTITUT PASTEUR   (France)

Author keywords

Eradication; HIV controllers; Inflammation; Natural hosts of simian human immunodeficiency virus; Post treatment controllers

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; DISEASE; HUMAN IMMUNODEFICIENCY VIRUS; IMMUNE RESPONSE; RESEARCH; VACCINE;

EID: 84900312727     PISSN: 09628436     EISSN: 14712970     Source Type: Journal    
DOI: 10.1098/rstb.2013.0436     Document Type: Review

References (251)

1. Barre-Sinoussi F et al. 1983 Isolation of a T-lymphotropic retrovirus from a patient at risk for acquired immune deficiency syndrome (AIDS). Science 220, 868-871. (doi:10.1126/science. 6189183)
2. Deeks SG et al. 2012 Towards an HIV cure: a global scientific strategy. Nat. Rev. Immunol. 12, 607-614. (doi:10.1038/nri3262)
3. Hutter G et al. 2009 Long-term control of HIV by CCR5 Delta32/Delta32 stem-cell transplantation. N. Engl. J. Med. 360, 692-698. (doi:10.1056/ NEJMoa0802905)
4. Allers K, Hutter G, Hofmann J, Loddenkemper C, Rieger K, Thiel E, Schneider T. 2011 Evidence for the cure of HIV infection by CCR5D32/D32 stem cell transplantation. Blood 117, 2791-2799. (doi:10. 1182/blood-2010-09-309591)
5. Yukl SA et al. 2013 Challenges in detecting HIV persistence during potentially curative interventions: a study of the Berlin patient. PLoS Pathog. 9, e1003347. (doi:10.1371/journal.ppat.1003347)
6. Saez-Cirion A, Pancino G. 2013 HIV controllers: a genetically determined or inducible phenotype? Immunol. Rev. 254, 281-294. (doi:10.1111/imr. 12076)
7. Mellors JW, Rinaldo Jr CR, Gupta P, White RM, Todd JA, Kingsley LA. 1996 Prognosis in HIV-1 infection predicted by the quantity of virus in plasma. Science 272, 1167-1170. (doi:10.1126/science.272. 5265.1167)
8. Giorgi JV et al. 1999 Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J. Infect. Dis. 179, 859-870. (doi:10.1086/314660)
9. Sousa AE, Carneiro J, Meier-Schellersheim M, Grossman Z, Victorino RM. 2002 CD4 T cell depletion is linked directly to immune activation in the pathogenesis of HIV-1 and HIV-2 but only indirectly to the viral load. J. Immunol. 169, 3400-3406.
10. Hazenberg MD, Otto SA, van Benthem BH, Roos MT, Coutinho RA, Lange JM, Hamann D, Prins M, Miedema F. 2003 Persistent immune activation in HIV-1 infection is associated with progression to AIDS. AIDS 17, 1881-1888. (doi:10.1097/ 00002030-200309050-00006)
11. Kuller LH et al. 2008 Inflammatory and coagulation biomarkers and mortality in patients with HIV infection. PLoS Med. 5, e203. (doi:10.1371/journal. pmed.0050203)
12. Paiardini M, Müller-Trutwin M. 2013 HIV-associated chronic immune activation. Immunol. Rev. 254, 78-101. (doi:10.1111/imr.12079)
13. Liovat AS et al. 2012 Acute plasma biomarkers of T cell activation set-point levels and of disease progression in HIV-1 infection. PLoS ONE 7, e46143. (doi:10.1371/journal.pone.0046143)
14. Omer FM, de Souza JB, Riley EM. 2003 Differential induction of TGF-beta regulates proinflammatory cytokine production and determines the outcome of lethal and nonlethal Plasmodium yoelii infections. J. Immunol. 171, 5430-5436.
15. Zuniga EI, Liou LY, Mack L, Mendoza M, Oldstone MB. 2008 Persistent virus infection inhibits type I interferon production by plasmacytoid dendritic cells to facilitate opportunistic infections. Cell Host Microbe 4, 374-386. (doi:10.1016/j.chom.2008.08.016)
16. Sandler NG, Sereti I. 2014 Can early therapy reduce inflammation? Curr. Opin. HIV AIDS 9, 72-79. (doi:10.1097/COH.0000000000000020)
17. Saez-Cirion A et al. 2013 Post-treatment HIV-1 controllers with a long-term virological remission after the interruption of early initiated antiretroviral therapy ANRS VISCONTI study. PLoS Pathog. 9, e1003211. (doi:10.1371/journal.ppat.1003211)
18. Hocqueloux L, Prazuck T, Avettand-Fenoel V, Lafeuillade A, Cardon B, Viard JP, Rouzioux C. 2010 Long-term immunovirologic control following antiretroviral therapy interruption in patients treated at the time of primary HIV-1 infection. AIDS 24, 1598-1601. (doi:10.1097/QAD.0b013e32833b61ba)
19. Lodi S, Meyer L, Kelleher AD, Rosinska M, Ghosn J, Sannes M, Porter K. 2012 Immunovirologic control 24 months after interruption of antiretroviral therapy initiated close to HIV seroconversion. Arch. Intern. Med. 172, 1252-1255. (doi:10.1001/ archinternmed.2012.2719)
20. Goujard C et al. 2012 Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM trial. AIDS 26, 1895-1905. (doi:10.1097/QAD. 0b013e32835844d9)
21. Madec Y, Boufassa F, Rouzioux C, Delfraissy JF, Meyer L. 2005 Undetectable viremia without antiretroviral therapy in patients with HIV seroconversion: an uncommon phenomenon? Clin. Infect. Dis. 40, 1350-1354. (doi:10.1086/429318)
22. Goujard C et al. 2009 Spontaneous control of viral replication during primary HIV infection: when is 'HIV controller' status established? Clin. Infect. Dis. 49, 982-986. (doi:10.1086/605504)
23. Van Gulck E, Bracke L, Heyndrickx L, Coppens S, Atkinson D, Merlin C, Pasternak A, Florence E, Vanham G. 2012 Immune and viral correlates of 'secondary viral control' after treatment interruption in chronically HIV-1 infected patients. PLoS ONE 7, e37792. (doi:10.1371/journal.pone.0037792)
24. + count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 355, 2283-2296. (doi:10.1056/ NEJMoa062360)
25. Daniel MD, Kirchhoff F, Czajak SC, Sehgal PK, Desrosiers RC. 1992 Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 258, 1938-1941. (doi:10.1126/science.1470917)
26. Schindler M et al. 2006 Nef-mediated suppression of T cell activation was lost in a lentiviral lineage that gave rise to HIV-1. Cell 125, 1055-1067. (doi:10.1016/j.cell.2006.04.033)
27. + T cells. Nature 434, 1148-1152. (doi:10. 1038/nature03513)
28. + T cells in multiple tissues during acute SIV infection. Nature 434, 1093-1097. (doi:10.1038/nature03501)
29. + memory T cells in rapidly progressive simian immunodeficiency virus infection. J. Exp. Med. 200, 1299-1314. (doi:10. 1084/jem.20041049)
30. Veazey RS, Lackner AA. 2005 HIV swiftly guts the immune system. Nat. Med. 11, 469-470. (doi:10. 1038/nm0505-469)
31. Brenchley JM et al. 2006 Microbial translocation is a cause of systemic immune activation in chronic HIV infection. Nat. Med. 12, 1365-1371. (doi:10.1038/ nm1511)
32. + NK cells. J. Virol. 84, 8959-8963. (doi:10.1128/JVI. 01126-10)
33. Reeves RK, Evans TI, Gillis J, Wong FE, Kang G, Li Q, Johnson RP. 2012 SIV infection induces accumulation of plasmacytoid dendritic cells in the gut mucosa. J. Infect. Dis. 206, 1462-1468. (doi:10.1093/infdis/jis408)
34. Ansari AA et al. 2011 Blocking of alpha4beta7 guthoming integrin during acute infection leads to decreased plasma and gastrointestinal tissue viral loads in simian immunodeficiency virus-infected rhesus macaques. J. Immunol. 186, 1044-1059. (doi:10.4049/jimmunol.1003052)
35. Aarnink A, Dereuddre-Bosquet N, Vaslin B, Le Grand R, Winterton P, Apoil PA, Blancher A. 2011 Influence of the MHC genotype on the progression of experimental SIV infection in the Mauritian cynomolgus macaque. Immunogenetics 63, 267-274. (doi:10.1007/s00251-010-0504-6)
36. Karl JA, Bohn PS, Wiseman RW, Nimityongskul FA, Lank SM, Starrett GJ, O'Connor DH. 2013 Major histocompatibility complex class I haplotype diversity in Chinese rhesus macaques. G3 (Bethesda) 3, 1195-1201. (doi:10.1534/g3.113.006254)
37. Wu F et al. 2013 TRIM5 alpha drives SIVsmm evolution in rhesus macaques. PLoS Pathog. 9, e1003577. (doi:10.1371/journal.ppat.1003577)
38. +-T-cell loss in simian immunodeficiency virus SIVagm-infected pigtailed macaques: variable pathogenicity of natural SIVagm isolates. J. Virol. 79, 5153-5162. (doi:10.1128/JVI.79.8.5153-5162.2005)
39. + cell depletion. PLoS Pathog. 7, e1002170. (doi:10. 1371/journal.ppat.1002170)
40. Diop OM et al. 2000 High levels of viral replication during primary simian immunodeficiency virus SIVagm infection are rapidly and strongly controlled in African green monkeys. J. Virol. 74, 7538-7547. (doi:10.1128/JVI.74.16.7538-7547.2000)
41. Bourry O, Mannioui A, Sellier P, Roucairol C, Durand-Gasselin L, Dereuddre-Bosquet N, Benech H, Roques P, Le Grand R. 2010 Effect of a short-term HAART on SIV load in macaque tissues is dependent on time of initiation and antiviral diffusion. Retrovirology 7, 78. (doi:10.1186/1742-4690-7-78)
42. Cranage M et al. 2008 Prevention of SIV rectal transmission and priming of T cell responses in macaques after local pre-exposure application of tenofovir gel. PLoS Med. 5, e157. (doi:10.1371/ journal.pmed.0050157)
43. Apetrei C, Pandrea I, Mellors JW. 2012 Nonhuman primate models for HIV cure research. PLoS Pathog. 8, e1002892. (doi:10.1371/journal.ppat.1002892)
44. Shytaj IL. 2012 A highly intensified ART regimen induces long-term viral suppression and restriction of the viral reservoir in a simian AIDS model. PLoS Pathog. 8, e1002774. (doi:10.1371/journal.ppat.1002774)
45. Sodora DL et al. 2009 Toward an AIDS vaccine: lessons from natural simian immunodeficiency virus infections of African nonhuman primate hosts. Nat. Med. 15, 861-865. (doi:10.1038/nm.2013)
46. Liovat AS, Jacquelin B, Ploquin MJ, Barre-Sinoussi F, Muller-Trutwin MC. 2009 African non human primates infected by SIV-why don't they get sick? Lessons from studies on the early phase of nonpathogenic SIV infection. Curr. HIV Res. 7, 39-50. (doi:10.2174/157016209787048546)
47. Kornfeld C et al. 2005 Antiinflammatory profiles during primary SIV infection in African green monkeys are associated with protection against AIDS. J. Clin. Invest. 115, 1082-1091. (doi:10.1172/ JCI23006)
48. Douek DC. 2013 Immune activation, HIV persistence, and the cure. Top. Antiviral Med. 21, 128-132.
49. Boulet S, Sharafi S, Simic N, Bruneau J, Routy JP, Tsoukas CM, Bernard NF. 2008 Increased proportion of KIR3DS1 homozygotes in HIV-exposed uninfected individuals. AIDS 22, 595-599. (doi:10.1097/QAD. 0b013e3282f56b23)
50. Jennes W, Verheyden S, Demanet C, Adje-Toure CA, Vuylsteke B, Nkengasong JN, Kestens L. 2006 Cutting edge: resistance to HIV-1 infection among African female sex workers is associated with inhibitory KIR in the absence of their HLA ligands. J. Immunol. 177, 6588-6592.
51. + cells in sexually HIV-1-exposed but uninfected individuals. Clin. Immunol. 120, 138-146. (doi:10.1016/j.clim.2006.02.008)
52. Ravet S et al. 2007 Distinctive NK-cell receptor repertoires sustain high-level constitutive NK-cell activation in HIV-exposed uninfected individuals. Blood 109, 4296-4305. (doi:10.1182/blood-2006-08-040238)
53. Scott-Algara D, Truong LX, Versmisse P, David A, Luong TT, Nguyen NV, Theodorou I, Barre-Sinoussi F, Pancino G. 2003 Cutting edge: increased NK cell activity in HIV-1-exposed but uninfected Vietnamese intravascular drug users. J. Immunol. 171, 5663-5667.
54. Alter G, Teigen N, Ahern R, Streeck H, Meier A, Rosenberg ES, Altfeld M. 2007 Evolution of innate and adaptive effector cell functions during acute HIV-1 infection. J. Infect. Dis. 195, 1452-1460. (doi:10.1086/513878)
55. Alter G et al. 2005 Sequential deregulation of NK cell subset distribution and function starting in acute HIV-1 infection. Blood 106, 3366-3369. (doi:10.1182/blood-2005-03-1100)
56. Jost S, Altfeld M. 2012 Evasion from NK cell-mediated immune responses by HIV-1. Microbes Infect. 14, 904-915. (doi:10.1016/j.micinf.2012.05.001)
57. Martin MP et al. 2002 Epistatic interaction between KIR3DS1 and HLA-B delays the progression to AIDS. Nat. Genet. 31, 429-434. (doi:10.1038/ng934)
58. Martin MP et al. 2007 Innate partnership of HLA-B and KIR3DL1 subtypes against HIV-1. Nat. Genet. 39, 733-740. (doi:10.1038/ng2035)
59. + NK cells during acute human immunodeficiency virus type 1 infection. J. Virol. 83, 6798-6805. (doi:10.1128/JVI.00256-09)
60. Kim S et al. 2008 HLA alleles determine differences in human natural killer cell responsiveness and potency. Proc. Natl Acad. Sci. USA 105, 3053-3058. (doi:10.1073/pnas.0712229105)
61. Fadda L et al. 2010 Peptide antagonism as a mechanism for NK cell activation. Proc. Natl Acad. Sci. USA 107, 10 160-10 165. (doi:10.1073/pnas. 0913745107)
62. Thananchai H et al. 2007 Cutting edge: allelespecific and peptide-dependent interactions between KIR3DL1 and HLA-A and HLA-B. J. Immunol. 178, 33-37.
63. Vivian JP et al. 2011 Killer cell immunoglobulin-like receptor 3DL1-mediated recognition of human leukocyte antigen B. Nature 479, 401-405. (doi:10. 1038/nature10517)
64. Alter G et al. 2011 HIV-1 adaptation to NK-cellmediated immune pressure. Nature 476, 96-100. (doi:10.1038/nature10237)
65. Migueles SA et al. 2000 HLA B*5701 is highly associated with restriction of virus replication in a subgroup of HIV-infected long term nonprogressors. Proc. Natl Acad. Sci. USA 97, 2709-2714. (doi:10. 1073/pnas.050567397)
66. Pereyra F et al. 2010 The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330, 1551-1557. (doi:10.1126/science.1195271)
67. Saez-Cirion A et al. 2007 HIV controllers exhibit potent CD8 T cell capacity to suppress HIV infection ex vivo and peculiar cytotoxic T lymphocyte activation phenotype. Proc. Natl Acad. Sci. USA 104, 6776-6781. (doi:10.1073/pnas. 0611244104)
68. Flores-Villanueva PO et al. 2001 Control of HIV-1 viremia and protection from AIDS are associated with HLA-Bw4 homozygosity. Proc. Natl Acad. Sci. USA 98, 5140-5145. (doi:10.1073/pnas. 071548198)
69. Marras F et al. 2013 Natural killer cells in HIV controller patients express an activated effector phenotype and do not up-regulate NKp44 on IL-2 stimulation. Proc. Natl Acad. Sci. USA 110, 11 970-11 975. (doi:10.1073/pnas.1302090110)
70. Tomescu C, Duh FM, Hoh R, Viviani A, Harvill K, Martin MP, Carrington M, Deeks SG, Montaner LJ. 2012 Impact of protective killer inhibitory receptor/ human leukocyte antigen genotypes on natural killer cell and T-cell function in HIV-1-infected controllers. AIDS 26, 1869-1878. (doi:10.1097/ QAD.0b013e32835861b0)
71. Vieillard V, Fausther-Bovendo H, Samri A, Debre P. 2010 Specific phenotypic and functional features of natural killer cells from HIV-infected long-term nonprogressors and HIV controllers. J. Acquir. Immune Defic. Syndr. 53, 564-573. (doi:10.1097/ QAI.0b013e3181d0c5b4)
72. O'Connell KA, Han Y, Williams TM, Siliciano RF, Blankson JN. 2009 Role of natural killer cells in a cohort of elite suppressors: low frequency of the protective KIR3DS1 allele and limited inhibition of human immunodeficiency virus type 1 replication in vitro. J. Virol. 83, 5028-5034. (doi:10.1128/JVI. 02551-08)
73. Muller-Trutwin M, Hosmalin A. 2005 Role for plasmacytoid dendritic cells in anti-HIV innate immunity. Immunol. Cell Biol. 83, 578-583. (doi:10.1111/j.1440-1711.2005.01394.x)
74. Pillai SK et al. 2012 Role of retroviral restriction factors in the interferon-alpha-mediated suppression of HIV-1 in vivo. Proc. Natl Acad. Sci. USA 109, 3035-3040. (doi:10.1073/pnas. 1111573109)
75. Poli G, Orenstein JM, Kinter A, Folks TM, Fauci AS. 1989 Interferon-alpha but not AZT suppresses HIV expression in chronically infected cell lines. Science 244, 575-577. (doi:10.1126/science.2470148)
76. Torriani FJ et al. 2004 Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection in HIV-infected patients. N. Engl. J. Med. 351, 438-450. (doi:10.1056/NEJMoa040842)
77. Yamamoto JK, Barre-Sinoussi F, Bolton V, Pedersen NC, Gardner MB. 1986 Human alpha-and betainterferon but not gamma suppress the in vitro replication of LAV, HTLV-III, and ARV-2. J. Interferon Res. 6, 143-152. (doi:10.1089/jir.1986.6.143)
78. + cells from individuals with Aicardi-Goutieres syndrome are highly susceptible to HIV-1 infection. PLoS Pathog. 7, e1002425. (doi:10.1371/journal.ppat. 1002425)
79. Carthagena L et al. 2009 Human TRIM gene expression in response to interferons. PLoS ONE 4, e4894. (doi:10.1371/journal.pone.0004894)
80. Goujon C et al. 2013 Human MX2 is an interferoninduced post-entry inhibitor of HIV-1 infection. Nature 502, 559-562. (doi:10.1038/nature12542)
81. Kane M et al. 2013 MX2 is an interferon-induced inhibitor of HIV-1 infection. Nature 502, 563-566. (doi:10.1038/nature12653)
82. Keele BF et al. 2008 Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proc. Natl Acad. Sci. USA 105, 7552-7557. (doi:10.1073/ pnas.0802203105)
83. Fenton-May AE et al. 2013 Relative resistance of HIV-1 founder viruses to control by interferonalpha. Retrovirology 10, 146. (doi:10.1186/1742-4690-10-146)
84. Parrish NF et al. 2013 Phenotypic properties of transmitted founder HIV-1. Proc. Natl Acad. Sci. USA 110, 6626-6633. (doi:10.1073/pnas.1304288110)
85. Seo YJ, Hahm B. 2010 Type I interferon modulates the battle of host immune system against viruses. Adv. Appl. Microbiol. 73, 83-101. (doi:10.1016/ S0065-2164(10)73004-5)
86. Haase AT. 2010 Targeting early infection to prevent HIV-1 mucosal transmission. Nature 464, 217-223. (doi:10.1038/nature08757)
87. Favre D et al. 2010 Tryptophan catabolism by indoleamine 2,3-dioxygenase 1 alters the balance of TH17 to regulatory T cells in HIV disease. Sci. Transl. Med. 2, 32ra36. (doi:10.1126/scitranslmed.3000632)
88. Herbeuval JP et al. 2006 Differential expression of IFN-alpha and TRAIL/DR5 in lymphoid tissue of progressor versus nonprogressor HIV-1-infected patients. Proc. Natl Acad. Sci. USA 103, 7000-7005. (doi:10.1073/pnas.0600363103)
89. Malleret B et al. 2008 Primary infection with simian immunodeficiency virus: plasmacytoid dendritic cell homing to lymph nodes, type I interferon, and immune suppression. Blood 112, 4598-4608. (doi:10.1182/blood-2008-06-162651)
90. Barblu L, Machmach K, Gras C, Delfraissy JF, Boufassa F, Leal M, Ruiz-Mateos E, Lambotte O, Herbeuval JP. 2012 Plasmacytoid dendritic cells (pDCs) from HIV controllers produce interferonalpha and differentiate into functional killer pDCs under HIV activation. J. Infect. Dis. 206, 790-801. (doi:10.1093/infdis/jis384)
91. Machmach K et al. 2012 Plasmacytoid dendritic cells reduce HIV production in elite controllers. J. Virol. 86, 4245-4252. (doi:10.1128/JVI.07114-11)
92. Bergamaschi A, David A, Le Rouzic E, Nisole S, Barre-Sinoussi F, Pancino G. 2009 The CDK inhibitor p21Cip1/WAF1 is induced by FcgR activation and restricts the replication of human immunodeficiency virus type 1 and related primate lentiviruses in human macrophages. J. Virol. 83, 12 253-12 265. (doi:10.1128/JVI.01395-09)
93. Krupp A, McCarthy KR, Ooms M, Letko M, Morgan JS, Simon V, Johnson WE. 2013 APOBEC3G polymorphism as a selective barrier to cross-species transmission and emergence of pathogenic SIV and AIDS in a primate host. PLoS Pathog. 9, e1003641. (doi:10.1371/journal.ppat.1003641)
94. Malim MH, Bieniasz PD. 2012 HIV restriction factors and mechanisms of evasion. Cold Spring Harb. Perspect. Med. 2, a006940. (doi:10.1101/ cshperspect.a006940)
95. van Manen D, Rits MA, Beugeling C, van Dort K, Schuitemaker H, Kootstra NA. 2008 The effect of Trim5 polymorphisms on the clinical course of HIV-1 infection. PLoS Pathog. 4, e18. (doi:10.1371/journal. ppat.0040018)
96. + T lymphocytes of controllers in vivo. PLoS ONE 8, e76002. (doi:10.1371/journal.pone.0076002)
97. Do H et al. 2005 Exhaustive genotyping of the CEM15 (APOBEC3G) gene and absence of association with AIDS progression in a French cohort. J. Infect. Dis. 191, 159-163. (doi:10.1086/426826)
98. Sewram S, Singh R, Kormuth E, Werner L, Mlisana K, Karim SS, Ndung'u T. 2009 Human TRIM5alpha expression levels and reduced susceptibility to HIV-1 infection. J. Infect. Dis. 199, 1657-1663. (doi:10. 1086/598861)
99. + T-cells from HIV-1-infected individuals. PLoS Pathog. 6, e1000781. (doi:10.1371/journal.ppat.1000781)
100. Paxton WA et al. 1996 Relative resistance to HIV-1 infection of CD4 lymphocytes from persons who remain uninfected despite multiple high-risk sexual exposure. Nat. Med. 2, 412-417. (doi:10.1038/ nm0496-412)
101. Saez-Cirion A, Versmisse P, Truong LX, Chakrabarti LA, Carpentier W, Barre-Sinoussi F, Scott-Algara D, Pancino G. 2006 Persistent resistance to HIV-1 infection in CD4 T cells from exposed uninfected Vietnamese individuals is mediated by entry and post-entry blocks. Retrovirology 3, 81. (doi:10.1186/ 1742-4690-3-81)
102. + T cells from elite controllers resist HIV-1 infection by selective upregulation of p21. J. Clin. Invest. 121, 1549-1560. (doi:10.1172/JCI44539)
103. + T cells from HIV controllers. Blood 118, 955-964. (doi:10.1182/ blood-2010-12-327106)
104. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD. 1994 Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J. Virol. 68, 4650-4655.
105. Borrow P et al. 1997 Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nat. Med. 3, 205-211. (doi:10. 1038/nm0297-205)
106. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat. Med. 13, 46-53. (doi:10.1038/ nm1520)
107. Riviere Y et al. 1995 Gag-specific cytotoxic responses to HIV type 1 are associated with a decreased risk of progression to AIDS-related complex or AIDS. AIDS Res. Hum. Retroviruses 11, 903-907. (doi:10.1089/ aid.1995.11.903)
108. Martinez-Picado J et al. 2006 Fitness cost of escape mutations in p24 Gag in association with control of human immunodeficiency virus type 1. J. Virol. 80, 3617-3623. (doi:10.1128/JVI.80.7.3617-3623.2006)
109. Matano T, Shibata R, Siemon C, Connors M, Lane HC, Martin MA. 1998 Administration of an anti-CD8 monoclonal antibody interferes with the clearance of chimeric simian/human immunodeficiency virus during primary infections of rhesus macaques. J. Virol. 72, 164-169.
110. + lymphocyte depletion but does not account for accelerated SIV pathogenesis. J. Exp. Med. 206, 1575-1588. (doi:10.1084/jem.20090356)
111. + T cell depletion in simian immunodeficiency virus-infected macaques. J. Exp. Med. 189, 991-998. (doi:10.1084/jem.189.6.991)
112. + lymphocytes using a mouse-human chimeric monoclonal antibody. Am. J. Pathol. 154, 1923-1932. (doi:10. 1016/S0002-9440(10)65450-8)
113. + T cells. Science 270, 1811-1815. (doi:10.1126/science.270.5243.1811)
114. + lymphocytes can control HIV infection in vitro by suppressing virus replication. Science 234, 1563-1566. (doi:10.1126/science.2431484)
115. + T cell-mediated protection against an intracellular bacterium by perforin-dependent cytotoxicity. Eur. J. Immunol. 24, 3068-3072. (doi:10.1002/eji.1830241223)
116. Lowin B, Hahne M, Mattmann C, Tschopp J. 1994 Cytolytic T-cell cytotoxicity is mediated through perforin and Fas lytic pathways. Nature 370, 650-652. (doi:10.1038/370650a0)
117. Youngblood B, Wherry EJ, Ahmed R. 2012 Acquired transcriptional programming in functional and exhausted virus-specific CD8 T cells. Curr. Opin. HIV AIDS 7, 50-57. (doi:10.1097/COH.0b013e328 34ddcf2)
118. Champagne P et al. 2001 Skewed maturation of memory HIV-specific CD8 T lymphocytes. Nature 410, 106-111. (doi:10.1038/35065118)
119. + T-cell differentiation towards senescence in HIV-1 infection. PLoS Biol. 2, E20. (doi:10.1371/journal. pbio.0020020)
120. + T cells in HIVinfected progressors and long-term nonprogressors. J. Immunol. 165, 1082-1092.
121. + T cells. Blood 107, 4781-4789. (doi:10.1182/blood-2005-12-4818)
122. + T cell proliferation is coupled to perforin expression and is maintained in nonprogressors. Nat. Immunol. 3, 1061-1068. (doi:10.1038/ni845)
123. Hersperger AR, Makedonas G, Betts MR. 2008 Flow cytometric detection of perforin upregulation in human CD8 T cells. Cytometry A 73, 1050-1057. (doi:10.1002/cyto.a.20596)
124. + T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29, 1009-1021. (doi:10.1016/j.immuni. 2008.10.010)
125. Saez-Cirion A et al. 2009 Heterogeneity in HIV suppression by CD8 T cells from HIV controllers: association with Gag-specific CD8 T cell responses. J. Immunol. 182, 7828-7837. (doi:10.4049/ jimmunol.0803928)
126. + T lymphocytes recognize infected cells before AIDSvirus integration and viral protein expression. J. Immunol. 178, 2746-2754.
127. Lecuroux C et al. 2013 CD8 T-cells from most HIVinfected patients lack ex vivo HIV-suppressive capacity during acute and early infection. PLoS ONE 8, e59767. (doi:10.1371/journal.pone.0059767)
128. Trautmann L et al. 2012 Profound metabolic, functional, and cytolytic differences characterize HIV-specific CD8 T cells in primary and chronic HIV infection. Blood 120, 3466-3477. (doi:10.1182/ blood-2012-04-422550)
129. + T cells. Immunity 38, 425-436. (doi:10.1016/j.immuni.2012.11.021)
130. Chen H et al. 2012 TCR clonotypes modulate the protective effect of HLA class I molecules in HIV-1 infection. Nat. Immunol. 13, 691-700. (doi:10. 1038/ni.2342)
131. Huang J et al. 2011 Dendritic cell dysfunction during primary HIV-1 infection. J. Infect. Dis. 204, 1557-1562. (doi:10.1093/infdis/jir616)
132. Huang J, Burke PS, Cung TD, Pereyra F, Toth I, Walker BD, Borges L, Lichterfeld M, Yu XG. 2010 Leukocyte immunoglobulin-like receptors maintain unique antigen-presenting properties of circulating myeloid dendritic cells in HIV-1-infected elite controllers. J. Virol. 84, 9463-9471. (doi:10.1128/ JVI.01009-10)
133. Emu B, Sinclair E, Hatano H, Ferre A, Shacklett B, Martin JN, McCune JM, Deeks SG. 2008 HLA class Irestricted T-cell responses may contribute to the control of human immunodeficiency virus infection, but such responses are not always necessary for long-term virus control. J. Virol. 82, 5398-5407. (doi:10.1128/JVI.02176-07)
134. Pereyra F et al. 2008 Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. J. Infect. Dis. 197, 563-571. (doi:10.1086/526786)
135. + T cell responses maintain highly functional, broadly directed central memory responses. J. Virol. 86, 6959-6969. (doi:10.1128/ JVI.00531-12)
136. Shan L et al. 2012 Stimulation of HIV-1-specific cytolytic T lymphocytes facilitates elimination of latent viral reservoir after virus reactivation. Immunity 36, 491-501. (doi:10.1016/j.immuni. 2012.01.014)
137. + T cells. Nature 417, 95-98. (doi:10. 1038/417095a)
138. Benlahrech A et al. 2009 Adenovirus vector vaccination induces expansion of memory CD4 T cells with a mucosal homing phenotype that are readily susceptible to HIV-1. Proc. Natl Acad. Sci. USA 106, 19 940-19 945. (doi:10.1073/pnas. 0907898106)
139. Papagno L et al. 2011 Comprehensive analysis of virus-specific T-cells provides clues for the failure of therapeutic immunization with ALVAC-HIV vaccine. AIDS 25, 27-36. (doi:10.1097/QAD.0b013e328 340fe55)
140. de Souza MS et al. 2012 The Thai phase III trial (RV144) vaccine regimen induces T cell responses that preferentially target epitopes within the V2 region of HIV-1 envelope. J. Immunol. 188, 5166-5176. (doi:10.4049/jimmunol.1102756)
141. Frater J et al. 2014 HIV-1 specific CD4 responses in primary HIV-1 infection predict disease progression in the SPARTAC trial. AIDS 28, 699-708. (doi:10. 1097/QAD.0000000000000130)
142. + T cells and macrophages. J. Virol. 83, 7668-7677. (doi:10.1128/JVI.00513-09)
143. + T-cells: the holy grail? Clin. Exp. Immunol. 138, 10-13. (doi:10.1111/j.1365-2249.2004.02605.x)
144. Soghoian DZ et al. 2012 HIV-specific cytolytic CD4 T cell responses during acute HIV infection predict disease outcome. Sci. Transl. Med. 4, 123ra125. (doi:10.1126/scitranslmed.3003165)
145. + T lymphocytes. Proc. Natl Acad. Sci. USA 97, 3382-3387. (doi:10.1073/ pnas.97.7.3382)
146. Emu B et al. 2005 Phenotypic, functional, and kinetic parameters associated with apparent T-cell control of human immunodeficiency virus replication in individuals with and without antiretroviral treatment. J. Virol. 79, 14 169-14 178. (doi:10.1128/JVI.79.22.14169-14178.2005)
147. + T-cell subsets in human immunodeficiency virus controllers: an ANRS EP36 study. J. Virol. 81, 13 904-13 915. (doi:10. 1128/JVI.01401-07)
148. Vingert B et al. 2012 HIV controllers maintain a population of highly efficient Th1 effector cells in contrast to patients treated in the long term. J. Virol. 86, 10 661-10 674. (doi:10.1128/JVI. 00056-12)
149. + T cells correlates with disease progression and defines a reversible immune dysfunction. Nat. Immunol. 8, 1246-1254. (doi:10. 1038/ni1515)
150. +) T cells during HIV infection. Nat. Med. 14, 266-274. (doi:10.1038/nm1728)
151. + T cells respond to minimal amounts of Gag antigen due to high TCR avidity. PLoS Pathog. 6, e1000780. (doi:10. 1371/journal.ppat.1000780)
152. + T-cell responses. J. Virol. 84, 11 020-11 029. (doi:10.1128/JVI.00980-10)
153. Perreau M, Savoye AL, De Crignis E, Corpataux JM, Cubas R, Haddad EK, De Leval L, Graziosi C, Pantaleo G. 2013 Follicular helper T cells serve as the major CD4 T cell compartment for HIV-1 infection, replication, and production. J. Exp. Med. 210, 143-156. (doi:10.1084/jem.20121932)
154. Xu Y et al. 2013 Simian immunodeficiency virus infects follicular helper CD4 T cells in lymphoid tissues during pathogenic infection of pigtail macaques. J. Virol. 87, 3760-3773. (doi:10.1128/ JVI.02497-12)
155. + T cells and lymphoid tissue viral burden distinguish progressive and nonprogressive lentiviral infections. Blood 120, 4172-4181. (doi:10.1182/blood-2012-06-437608)
156. + T cells during simian immunodeficiency virus infection: T/B cell homeostasis, activation, and potential mechanism for viral escape. J. Immunol. 188, 3247-3256. (doi:10.4049/jimmunol.1103138)
157. Lindqvist M et al. 2012 Expansion of HIV-specific T follicular helper cells in chronic HIV infection. J. Clin. Invest. 122, 3271-3280. (doi:10.1172/JCI64314)
158. Petrovas C et al. 2012 CD4 T follicular helper cell dynamics during SIV infection. J. Clin. Invest. 122, 3281-3294. (doi:10.1172/JCI63039)
159. Chevalier MF, Weiss L. 2012 The split personality of regulatory T cells in HIV infection. Blood 121, 29-37. (doi:10.1182/blood-2012-07-409755)
160. + regulatory T cells are highly increased in untreated HIV infection and normalize after suppressive HAART. Blood 108, 3072-3078. (doi:10.1182/blood-2006-04-016923)
161. Dandekar S, George MD, Baumler AJ. 2010 Th17 cells, HIV and the gut mucosal barrier. Curr. Opin. HIV AIDS 5, 173-178. (doi:10.1097/COH. 0b013e328335eda3)
162. Angin M et al. 2012 Preserved function of regulatory T cells in chronic HIV-1 infection despite decreased numbers in blood and tissue. J. Infect. Dis. 205, 1495-1500. (doi:10.1093/infdis/jis236)
163. Hunt PW et al. 2011 A low T regulatory cell response may contribute to both viral control and generalized immune activation in HIV controllers. PLoS ONE 6, e15924. (doi:10.1371/journal.pone. 0015924)
164. + elite controllers have low HIVspecific T-cell activation yet maintain strong, polyfunctional T-cell responses. AIDS 24, 1095-1105. (doi:10.1097/QAD.0b013e3283377a1e)
165. Simonetta F, Lecuroux C, Girault I, Goujard C, Sinet M, Lambotte O, Venet A, Bourgeois C. 2012 Early and long-lasting alteration of effector CD45RA-Foxp3high regulatory T-cell homeostasis during HIV infection. J. Infect. Dis. 205, 1510-1519. (doi:10.1093/infdis/jis235)
166. + T cells evade Treg cell suppression. Nat. Med. 17, 989-995. (doi:10.1038/ nm.2422)
167. Overbaugh J, Morris L. 2012 The antibody response against HIV-1. Cold Spring Harb. Perspect. Med. 2, a007039. (doi:10.1101/cshperspect.a007039)
168. Simek MD et al. 2009 Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337-7348. (doi:10.1128/JVI.00110-09)
169. Barouch DH et al. 2013 Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224-228. (doi:10.1038/nature12744)
170. Hirbod T, Broliden K. 2007 Mucosal immune responses in the genital tract of HIV-1-exposed uninfected women. J. Intern. Med. 262, 44-58. (doi:10.1111/j.1365-2796.2007.01822.x).
171. Kaul R et al. 1999 HIV-1-specific mucosal IgA in a cohort of HIV-1-resistant Kenyan sex workers. AIDS 13, 23-29. (doi:10.1097/00002030-199901140-00004)
172. Ngo-Giang-Huong N et al. 2001 HIV type 1-specific IgG2 antibodies: markers of helper T cell type 1 response and prognostic marker of long-term nonprogression. AIDS Res. Hum. Retroviruses 17, 1435-1446. (doi:10.1089/088922201753197105)
173. French MA et al. 2013 Isotype-switched immunoglobulin G antibodies to HIV Gag proteins may provide alternative or additional immune responses to 'protective' human leukocyte antigen-B alleles in HIV controllers. AIDS 27, 519-528. (doi:10.1097/QAD.0b013e32835cb720)
174. Lai JI, Licht AF, Dugast AS, Suscovich T, Choi I, Bailey-Kellogg C, Alter G, Ackerman ME. 2013 Divergent antibody subclass and specificity profiles but not protective HLA-B alleles are associated with variable antibody effector function among HIV-1 controllers. J. Virol. 88, 2799-2809. (doi:10.1128/ JVI.03130-13)
175. Lambotte O et al. 2009 Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23, 897-906. (doi:10.1097/QAD.0b013e328329f97d)
176. Deepe RN, Kistner-Griffin E, Martin JN, Deeks SG, Pandey JP. 2012 Epistatic interactions between Fc (GM) and FcgR genes and the host control of human immunodeficiency virus replication. Hum. Immunol. 73, 263-266. (doi:10.1016/j.humimm. 2011.12.008)
177. Liu Q, Sun Y, Rihn S, Nolting A, Tsoukas PN, Jost S, Cohen K, Walker B, Alter G. 2009 Matrix metalloprotease inhibitors restore impaired NK cellmediated antibody-dependent cellular cytotoxicity in human immunodeficiency virus type 1 infection. J. Virol. 83, 8705-8712. (doi:10.1128/JVI.02666-08)
178. Bonsignori M et al. 2012 Antibody-dependent cellular cytotoxicity-mediating antibodies from an HIV-1 vaccine efficacy trial target multiple epitopes and preferentially use the VH1 gene family. J. Virol. 86, 11 521-11 532. (doi:10.1128/JVI.01023-12)
179. Rerks-Ngarm S et al. 2009 Vaccination with ALVAC and AIDSVAX to prevent HIV-1 infection in Thailand. N. Engl. J. Med. 361, 2209-2220. (doi:10.1056/ NEJMoa0908492)
180. Allouch A et al. 2013 p21-mediated RNR2 repression restricts HIV-1 replication in macrophages by inhibiting dNTP biosynthesis pathway. Proc. Natl Acad. Sci. USA 110, E3997-E4006. (doi:10.1073/ pnas.1306719110)
181. Stoiber H, Banki Z, Wilflingseder D, Dierich MP. 2008 Complement-HIV interactions during all steps of viral pathogenesis. Vaccine 26, 3046-3054. (doi:10.1016/j.vaccine.2007.12.003)
182. Banki Z et al. 2010 Complement as an endogenous adjuvant for dendritic cell-mediated induction of retrovirus-specific CTLs. PLoS Pathog. 6, e1000891. (doi:10.1371/journal.ppat.1000891)
183. Posch W et al. 2012 Antibodies attenuate the capacity of dendritic cells to stimulate HIVspecific cytotoxic T lymphocytes. J. Allergy Clin. Immunol. 130, 1368-1374. (doi:10.1016/j.jaci. 2012.08.025)
184. Pandrea I et al. 2012 Coagulation biomarkers predict disease progression in SIV-infected nonhuman primates. Blood 120, 1357-1366. (doi:10.1182/ blood-2012-03-414706)
185. Diop OM et al. 2008 Plasmacytoid dendritic cell dynamics and alpha interferon production during simian immunodeficiency virus infection with a nonpathogenic outcome. J. Virol. 82, 5145-5152. (doi:10.1128/JVI.02433-07)
186. Wijewardana V et al. 2013 Kinetics of myeloid dendritic cell trafficking and activation: impact on progressive, nonprogressive and controlled SIV infections. PLoS Pathog. 9, e1003600. (doi:10.1371/ journal.ppat.1003600)
187. Pereira LE, Johnson RP, Ansari AA. 2008 Sooty mangabeys and rhesus macaques exhibit significant divergent natural killer cell responses during both acute and chronic phases of SIV infection. Cell. Immunol. 254, 10-19. (doi:10.1016/j.cellimm.2008.06.006)
188. Bosinger SE et al. 2013 Intact type i interferon production and IRF7 function in sooty mangabeys. PLoS Pathog. 9, e1003597. (doi:10.1371/journal. ppat.1003597)
189. Jacquelin B et al. 2009 Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J. Clin. Invest. 119, 3544-3555. (doi:10.1172/JCI40093)
190. Jacquelin B, Zahn RC, Barré-Sinoussi F, Schmitz JE, Kaur A, Müller-Trutwin MC. 2011 Natural SIV infection: immunological aspects. In Models of protection against HIV/SIV: avoiding AIDS in humans and monkeys (eds G Pancino, G Silvestri, K Fowke), pp. 47-80. San Diego, CA: Academic Press.
191. Descours B et al. 2012 Immune responses driven by protective human leukocyte antigen alleles from long-term nonprogressors are associated with low HIV reservoir in central memory CD4 T cells. Clin. Infect. Dis. 54, 1495-1503. (doi:10.1093/cid/cis188)
192. Choudhary SK, Vrisekoop N, Jansen CA, Otto SA, Schuitemaker H, Miedema F, Camerini D. 2007 Low immune activation despite high levels of pathogenic human immunodeficiency virus type 1 results in long-term asymptomatic disease. J. Virol. 81, 8838-8842. (doi:10.1128/JVI.02663-06)
193. + T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J. Infect. Dis. 197, 126-133. (doi:10.1086/524143)
194. Hsue PY, Hunt PW, Schnell A, Kalapus SC, Hoh R, Ganz P, Martin JN, Deeks SG. 2009 Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosis. AIDS 23, 1059-1067. (doi:10.1097/QAD. 0b013e32832b514b)
195. Pereyra F et al. 2012 Increased coronary atherosclerosis and immune activation in HIV-1 elite controllers. AIDS 26, 2409-2412. (doi:10.1097/ QAD.0b013e32835a9950)
196. Krishnan S, Wilson EM, Sheikh V, Rupert A, Mendoza D, Yang J, Lempicki R, Migueles SA, Sereti I. 2013 Evidence for innate immune system activation in HIV Type 1-infected elite controllers. J. Infect. Dis. 209, 931-939. (doi:10.1093/infdis/ jit581)
197. + T-cell counts in HIV controller patients. AIDS 28, 467-476. (doi:10.1097/QAD.0000000000000174)
198. Hatano H et al. 2009 Evidence for persistent lowlevel viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. J. Virol. 83, 329-335. (doi:10.1128/JVI.01763-08)
199. Boufassa F et al. 2011 CD4 dynamics over a 15 yearperiod among HIV controllers enrolled in the ANRS French observatory. PLoS ONE 6, e18726. (doi:10. 1371/journal.pone.0018726)
200. Vigneault F et al. 2011 Transcriptional profiling of CD4 T cells identifies distinct subgroups of HIV-1 elite controllers. J. Virol. 85, 3015-3019. (doi:10. 1128/JVI.01846-10)
201. + T cell responses restrict SIV replication to follicular helper T cells. In 31st Annual Symp. on Nonhuman Primate Models for AIDS. Atlanta, GA, USA, 3-6 November 2013.
202. Racz P, Tenner-Racz K, van Vloten F, Schmidt H, Dietrich M, Gluckman JC, Letvin NL, Janossy G. 1990 Lymphatic tissue changes in AIDS and other retrovirus infections: tools and insights. Lymphology 23, 85-91.
203. + T cell depletion. J. Immunol. 181, 6687-6691.
204. Passaes CP, Saez-Cirion A. In press. HIV cure research: advances and prospects. Virology. (doi:10. 1016/j.virol.2014.02.021)
205. Persaud D, Gay H, Ziemniak C, Chen YH, Piatak Jr M, Chun TW, Strain M, Richman D, Luzuriaga K. 2013 Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 369, 1828-1835. (doi:10.1056/NEJMoa1302976)
206. Ngo-Giang-Huong N et al. 2001 Proviral HIV-1 DNA in subjects followed since primary HIV-1 infection who suppress plasma viral load after one year of highly active antiretroviral therapy. AIDS 15, 665-673. (doi:10.1097/00002030-200104130-00001)
207. Delwart E, Magierowska M, Royz M, Foley B, Peddada L, Smith R, Heldebrant C, Conrad A, Busch M. 2002 Homogeneous quasispecies in 16 out of 17 individuals during very early HIV-1 primary infection. AIDS 16, 189-195. (doi:10.1097/ 00002030-200201250-00007)
208. Moir S et al. 2010 B cells in early and chronic HIV infection: evidence for preservation of immune function associated with early initiation of antiretroviral therapy. Blood 116, 5571-5579. (doi:10.1182/blood-2010-05-285528)
209. Leone A, Picker LJ, Sodora DL. 2009 IL-2, IL-7 and IL-15 as immuno-modulators during SIV/HIV vaccination and treatment. Curr. HIV Res. 7, 83-90. (doi:10.2174/157016209787048519)
210. Levy Y et al. 2009 Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment. J. Clin. Invest. 119, 997-1007. (doi:10.1172/JCI38052)
211. Levy Y et al. 2012 Effects of recombinant human interleukin 7 on T-cell recovery and thymic output in HIV-infected patients receiving antiretroviral therapy: results of a phase I/IIa randomized, placebo-controlled, multicenter study. Clin. Infect. Dis. 55, 291-300. (doi:10.1093/cid/cis383)
212. Vandergeeten C et al. 2013 Interleukin-7 promotes HIV persistence during antiretroviral therapy. Blood 121, 4321-4329. (doi:10.1182/blood-2012-11-465625)
213. Asmuth DM et al. 2010 Safety, tolerability, and mechanisms of antiretroviral activity of pegylated interferon Alfa-2a in HIV-1-monoinfected participants: a phase II clinical trial. J. Infect. Dis. 201, 1686-1696. (doi:10.1086/652420)
214. Azzoni L et al. 2013 Pegylated Interferon alfa-2a monotherapy results in suppression of HIV type 1 replication and decreased cell-associated HIV DNA integration. J. Infect. Dis. 207, 213-222. (doi:10. 1093/infdis/jis663)
215. Boue F, Reynes J, Rouzioux C, Emilie D, Souala F, Tubiana R, Goujard C, Lancar R, Costagliola D. 2011 Alpha interferon administration during structured interruptions of combination antiretroviral therapy in patients with chronic HIV-1 infection: INTERVAC ANRS 105 trial. AIDS 25, 115-118. (doi:10.1097/ QAD.0b013e328340a1e7)
216. Porichis F, Kaufmann DE. 2012 Role of PD-1 in HIV pathogenesis and as target for therapy. Curr. HIV/ AIDS Rep. 9, 81-90. (doi:10.1007/s11904-011-0106-4)
217. Velu V et al. 2009 Enhancing SIV-specific immunity in vivo by PD-1 blockade. Nature 458, 206-210. (doi:10.1038/nature07662)
218. Velu V, Mylvaganam G, Freeman G, Ahmed R, Amara R. 2013 PD-1 blockade as an adjunct therapy for ART: improves anti-SIV immunity, virologic response to ART and gut CD4 T cell restoration. In 31st Annual Symp. on Nonhuman Primate Models for AIDS, Atlanta, GA, USA, 3-6 November 2013.
219. Chomont N et al. 2009 HIV reservoir size and persistence are driven by T cell survival and homeostatic proliferation. Nat. Med. 15, 893-900. (doi:10.1038/nm.1972)
220. Dyavar Shetty R, Velu V, Titanji K, Bosinger SE, Freeman GJ, Silvestri G, Amara RR. 2012 PD-1 blockade during chronic SIV infection reduces hyperimmune activation and microbial translocation in rhesus macaques. J. Clin. Invest. 122, 1712-1716. (doi:10.1172/JCI60612)
221. Hatano H. 2013 Immune activation and HIV persistence: considerations for novel therapeutic interventions. Curr. Opin. HIV AIDS 8, 211-216. (doi:10.1097/COH.0b013e32835f9788)
222. Sperber K, Chiang G, Chen H, Ross W, Chusid E, Gonchar M, Chow R, Liriano O. 1997 Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with human immunodeficiency virus type 1. Clin. Ther. 19, 913-923. (doi:10.1016/S0149-2918(97)80045-8)
223. Sperber K, Louie M, Kraus T, Proner J, Sapira E, Lin S, Stecher V, Mayer L. 1995 Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin. Ther. 17, 622-636. (doi:10.1016/ 0149-2918(95)80039-5)
224. Martinson JA, Montoya CJ, Usuga X, Ronquillo R, Landay AL, Desai SN. 2010 Chloroquine modulates HIV-1-induced plasmacytoid dendritic cell alpha interferon: implication for T-cell activation. Antimicrob. Agents Chemother. 54, 871-881. (doi:10.1128/AAC.01246-09)
225. Murray SM, Down CM, Boulware DR, Stauffer WM, Cavert WP, Schacker TW, Brenchley JM, Douek DC. 2010 Reduction of immune activation with chloroquine therapy during chronic HIV infection. J. Virol. 84, 12 082-12 086. (doi:10.1128/JVI. 01466-10)
226. Paton NI et al. 2012 Effects of hydroxychloroquine on immune activation and disease progression among HIV-infected patients not receiving antiretroviral therapy: a randomized controlled trial. JAMA 308, 353-361. (doi:10.1001/jama.2012.6936)
227. Funderburg NT, Jiang Y, Debanne SM, Storer N, Labbato D, Clagett B, Robinson J, Lederman MM, McComsey GA. 2013 Rosuvastatin treatment reduces markers of monocyte activation in HIV-infected subjects on antiretroviral therapy. Clin. Infect. Dis. 58, 588-596. (doi:10.1093/cid/cit748)
228. Overton ET, Kitch D, Benson CA, Hunt PW, Stein JH, Smurzynski M, Ribaudo HJ, Tebas P. 2013 Effect of statin therapy in reducing the risk of serious non-AIDS-defining events and nonaccidental death. Clin. Infect. Dis 56, 1471-1479. (doi:10.1093/cid/cit053)
229. Rasmussen LD, Kronborg G, Larsen CS, Pedersen C, Gerstoft J, Obel N. 2013 Statin therapy and mortality in HIV-infected individuals; a Danish nationwide population-based cohort study. PLoS ONE 8, e52828. (doi:10.1371/journal.pone.0052828)
230. Lichtenstein K et al. 2013 Statin use is associated with incident diabetes mellitus among patients in the HIV outpatient study. In 20th CROI, Atlanta, GA, USA, 3-6 March 2013. Abstract no. 767.
231. Takahashi Y et al. 2014 In vivo administration of a JAK3 inhibitor during acute SIV infection leads to significant increases in viral load during chronic infection. PLoS Pathog. 10, e1003929. (doi:10.1371/ journal.ppat.1003929)
232. Morlat P, Pereira E, Clayette P, Derreudre-Bosquet N, Ecobichon JL, Benveniste O, Saves M, Leport C. 2008 Early evolution of plasma soluble TNF-alpha p75 receptor as a marker of progression in treated HIVinfected patients. AIDS Res. Hum. Retroviruses 24, 1383-1389. (doi:10.1089/aid.2007.0293)
233. Ananworanich J et al. 2012 Impact of multitargeted antiretroviral treatment on gut T cell depletion and HIV reservoir seeding during acute HIV infection. PLoS ONE 7, e33948. (doi:10.1371/ journal.pone.0033948)
234. Gay C et al. 2011 Cross-sectional detection of acute HIV infection: timing of transmission, inflammation and antiretroviral therapy. PLoS ONE 6, e19617. (doi:10.1371/journal.pone.0019617)
235. Brown KC et al. 2011 Single and multiple dose pharmacokinetics of maraviroc in saliva, semen, and rectal tissue of healthy HIV-negative men. J. Infect. Dis. 203, 1484-1490. (doi:10.1093/infdis/jir059)
236. Puertas MC et al. 2013 Intensification of a raltegravir-based regimen with maraviroc in early HIV-1 infection. AIDS 28, 325-334. (doi:10.1097/ QAD.0000000000000066)
237. Hunt PW, Lederman MM, Deeks SG. 2013 Response: maraviroc intensification and microbial translocation. Blood 122, 2283-2284. (doi:10.1182/blood-2013-08-516930)
238. Psomas C et al. 2013 Maraviroc-induced decrease in circulating bacterial products is not linked to an increase in immune activation in HIV-infected individuals. Blood 122, 2282-2283. (doi:10.1182/ blood-2013-06-507012)
239. Hatano H et al. 2013 Prospective antiretroviral treatment of asymptomatic, HIV-1 infected controllers. PLoS Pathog. 9, e1003691. (doi:10.1371/ journal.ppat.1003691)
240. Garcia F et al. 2013 A dendritic cell-based vaccine elicits T cell responses associated with control of HIV-1 replication. Sci. Transl. Med. 5, 166ra162. (doi:10.1126/scitranslmed.3004682)
241. Trumpfheller C, Longhi MP, Caskey M, Idoyaga J, Bozzacco L, Keler T, Schlesinger SJ, Steinman RM. 2012 Dendritic cell-targeted protein vaccines: a novel approach to induce T-cell immunity. J. Intern. Med. 271, 183-192. (doi:10.1111/j.1365-2796. 2011.02496.x)
242. + T cells in mice. J. Clin. Invest. 123, 2629-2642. (doi:10.1172/JCI64704)
243. Hansen SG et al. 2011 Profound early control of highly pathogenic SIV by an effector memory T-cell vaccine. Nature 473, 523-527. (doi:10.1038/nature10003)
244. + T cell epitope recognition paradigms. Science 340, 1237874. (doi:10.1126/science.1237874)
245. Trkola A et al. 2005 Delay of HIV-1 rebound after cessation of antiretroviral therapy through passive transfer of human neutralizing antibodies. Nat. Med. 11, 615-622. (doi:10.1038/nm1244)
246. Moore PL et al. 2012 Evolution of an HIV glycandependent broadly neutralizing antibody epitope through immune escape. Nat. Med. 18, 1688-1692. (doi:10.1038/nm.2985)
247. Kwong PD, Mascola JR. 2012 Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37, 412-425. (doi:10. 1016/j.immuni.2012.08.012)
248. Liao HX et al. 2013 Co-evolution of a broadly neutralizing HIV-1 antibody and founder virus. Nature 496, 469-476. (doi:10.1038/nature 12053)
249. Jardine J et al. 2013 Rational HIV immunogen design to target specific germline B cell receptors. Science 340, 711-716. (doi:10.1126/science.1234150)
250. McGuire AT et al. 2013 Engineering HIV envelope protein to activate germline B cell receptors of broadly neutralizing anti-CD4 binding site antibodies. J. Exp. Med. 210, 655-663. (doi:10. 1084/jem.20122824)
251. Barouch DH et al. 2013 Protective efficacy of a global HIV-1 mosaic vaccine against heterologous SHIV challenges in rhesus monkeys. Cell 155, 531-539. (doi:10.1016/j.cell.2013.09.061)